May 15 (Reuters) - Travere Therapeutics Inc TVTX.O:
TRAVERE THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF SNDA FOR FILSPARI® (SPARSENTAN) IN FSGS
TRAVERE THERAPEUTICS INC - PDUFA TARGET ACTION DATE SET FOR JANUARY 13, 2026
TRAVERE THERAPEUTICS INC - FILSPARI COULD BE FIRST FDA-APPROVED TREATMENT FOR FSGS
Source text: ID:nBw3cJ84da
Further company coverage: TVTX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.